Drug Profile
Filgotinib - Galapagos/Gilead Sciences
Alternative Names: Filgotinib hydrochloride; Filgotinib Maleate; G-146034; G-146034-101; GLPG-0634; GS-6034; JyselecaLatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Galapagos NV
- Developer Eisai Co Ltd; Galapagos NV; Gilead Sciences
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Pyridines; Skin disorder therapies; Small molecules; Thiamorpholines; Triazoles; Urologics
- Mechanism of Action Janus kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Rheumatoid arthritis; Ulcerative colitis
- Phase III Axial spondyloarthritis
- Phase I Juvenile rheumatoid arthritis
- Discontinued Ankylosing spondylitis; Crohn's disease; Cutaneous lupus erythematosus; Lupus nephritis; Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Sjogren's syndrome; Uveitis
Most Recent Events
- 07 Mar 2024 Phase-I clinical trials in Juvenile rheumatoid arthritis (In children, In adolescents, Treatment-experienced) in France, Germany (PO) (NCT06222034) (EudraCT2023-505844-21-00)
- 31 Jan 2024 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
- 31 Jan 2024 Galapagos NV plans a phase I trial for Juvenile rheumatoid arthritis (In children, Treatment-experienced) in United Kingdom (PO) (NCT06222034)